• Explore /
  • Poster
  • / AvaALL: Open-label randomized phase IIIb trial evaluating the efficacy and safety of standard of care with or without continuous bevacizumab (BV) treatment beyond disease progression in patients (pts) with advanced nonsquamous non-small cell lung cancer (NSCLC) after first-line (1L) treatment with BV plus platinum-doublet chemotherapy (CT).

AvaALL: Open-label randomized phase IIIb trial evaluating the efficacy and safety of standard of care with or without continuous bevacizumab (BV) treatment beyond disease progression in patients (pts) with advanced nonsquamous non-small cell lung cancer (NSCLC) after first-line (1L) treatment with BV plus platinum-doublet chemotherapy (CT).

Abstract Poster

Authors

null

Cesare Gridelli

SG Moscati Hospital, Avellino, Italy

Cesare Gridelli , Jaafar Bennouna , Javier De Castro , Anne-Marie C. Dingemans , Frank Griesinger , Francesco Grossi , Nick Thatcher , Yuichiro Ohe , Pablo Diego Perez-Moreno , Corey J. Langer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer - Non-small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01351415

Citation

J Clin Oncol 30, 2012 (suppl; abstr TPS7612)

DOI

10.1200/jco.2012.30.15_suppl.tps7612

Abstract #

TPS7612

Poster Bd #

53F

Abstract Disclosures

Similar Posters

First Author: Martin Reck

First Author: Shigeto Maeda

First Author: Yuangyuan Zhao

First Author: Christian Grohé